Raspadori et al. (58) reported that CD56 was more often expressed by myeloblasts in FAB subclasses M2 and M5, which covers about 42% of AML cases in a study by Legrand et al. (56). This evidence concerns the gene NCAM1 and acute myeloid leukemia.